Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study

<i>Background and Objectives</i>: Ectopic pregnancy (EP) is a potentially life-threatening condition and the leading cause of maternal mortality in the first trimester. Although both surgical and medical approaches are effective, selection criteria for Methotrexate (MTX) treatment remain...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisa Scarpelli, Vito Andrea Capozzi, Licia Roberto, Asya Gallinelli, Alessandra Pezzani, Michela Monica, Roberto Berretta
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/6/1058
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849431514752745472
author Elisa Scarpelli
Vito Andrea Capozzi
Licia Roberto
Asya Gallinelli
Alessandra Pezzani
Michela Monica
Roberto Berretta
author_facet Elisa Scarpelli
Vito Andrea Capozzi
Licia Roberto
Asya Gallinelli
Alessandra Pezzani
Michela Monica
Roberto Berretta
author_sort Elisa Scarpelli
collection DOAJ
description <i>Background and Objectives</i>: Ectopic pregnancy (EP) is a potentially life-threatening condition and the leading cause of maternal mortality in the first trimester. Although both surgical and medical approaches are effective, selection criteria for Methotrexate (MTX) treatment remain inconsistent across international guidelines. Additionally, limited data on long-term reproductive outcomes are available. <i>Materials and Methods</i>: We conducted a single-center retrospective cohort study of 107 patients diagnosed with tubal EP and treated at the Obstetrics and Gynecology Unit of the University Hospital of Parma between 2019 and 2023. MTX (50 mg/m<sup>2</sup>) was offered to patients with β-hCG < 5000 mIU/mL, sac diameter < 40 mm, and no embryonic cardiac activity or hemoperitoneum; others underwent salpingectomy. Treatment outcomes, predictors of MTX success, and fertility outcomes were analyzed. <i>Results</i>: Medical treatment was offered to 36 patients (33.6%), with an overall success rate of 72%: in total, 20 resolved after a single dose and 6 after a second dose. Surgical conversion was necessary in 10 patients. The remaining 71 patients (66.4%) underwent primary salpingectomy. Initial β-hCG levels and gestational age did not significantly predict MTX failure (<i>p</i> 0.14 and 0.73, respectively), whereas gestational sac diameter was identified as a reliable predictor of treatment success (<i>p</i> = 0.01). In particular, a gestational sac maximum diameter of <2 cm emerged as a positive factor for MTX success (OR 1.13, 95% CI: 1.1–1.3, <i>p</i> = 0.04). Among the 50 patients with follow-up data, 68% achieved a term live birth, with no significant difference between the MTX (52.9%) and surgical (75.8%) groups (<i>p</i> 0.12). Most of the pregnancies (90%) occurred spontaneously, while only 10% required assisted reproductive technologies. <i>Conclusions</i>: MTX is a safe and effective treatment for tubal EP when patients are appropriately selected. Gestational sac diameter appears to be a reliable predictor of success. Both medical and surgical treatments yielded comparable reproductive outcomes, supporting individualized care models that prioritize fertility preservation.
format Article
id doaj-art-e8bc481892684a5b8e8e32c5eb90df92
institution Kabale University
issn 1010-660X
1648-9144
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-e8bc481892684a5b8e8e32c5eb90df922025-08-20T03:27:37ZengMDPI AGMedicina1010-660X1648-91442025-06-01616105810.3390/medicina61061058Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort StudyElisa Scarpelli0Vito Andrea Capozzi1Licia Roberto2Asya Gallinelli3Alessandra Pezzani4Michela Monica5Roberto Berretta6Department of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, ItalyDepartment of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, Italy<i>Background and Objectives</i>: Ectopic pregnancy (EP) is a potentially life-threatening condition and the leading cause of maternal mortality in the first trimester. Although both surgical and medical approaches are effective, selection criteria for Methotrexate (MTX) treatment remain inconsistent across international guidelines. Additionally, limited data on long-term reproductive outcomes are available. <i>Materials and Methods</i>: We conducted a single-center retrospective cohort study of 107 patients diagnosed with tubal EP and treated at the Obstetrics and Gynecology Unit of the University Hospital of Parma between 2019 and 2023. MTX (50 mg/m<sup>2</sup>) was offered to patients with β-hCG < 5000 mIU/mL, sac diameter < 40 mm, and no embryonic cardiac activity or hemoperitoneum; others underwent salpingectomy. Treatment outcomes, predictors of MTX success, and fertility outcomes were analyzed. <i>Results</i>: Medical treatment was offered to 36 patients (33.6%), with an overall success rate of 72%: in total, 20 resolved after a single dose and 6 after a second dose. Surgical conversion was necessary in 10 patients. The remaining 71 patients (66.4%) underwent primary salpingectomy. Initial β-hCG levels and gestational age did not significantly predict MTX failure (<i>p</i> 0.14 and 0.73, respectively), whereas gestational sac diameter was identified as a reliable predictor of treatment success (<i>p</i> = 0.01). In particular, a gestational sac maximum diameter of <2 cm emerged as a positive factor for MTX success (OR 1.13, 95% CI: 1.1–1.3, <i>p</i> = 0.04). Among the 50 patients with follow-up data, 68% achieved a term live birth, with no significant difference between the MTX (52.9%) and surgical (75.8%) groups (<i>p</i> 0.12). Most of the pregnancies (90%) occurred spontaneously, while only 10% required assisted reproductive technologies. <i>Conclusions</i>: MTX is a safe and effective treatment for tubal EP when patients are appropriately selected. Gestational sac diameter appears to be a reliable predictor of success. Both medical and surgical treatments yielded comparable reproductive outcomes, supporting individualized care models that prioritize fertility preservation.https://www.mdpi.com/1648-9144/61/6/1058ectopic pregnancymethotrexatesalpingectomytubal pregnancytubal rupturematernal death
spellingShingle Elisa Scarpelli
Vito Andrea Capozzi
Licia Roberto
Asya Gallinelli
Alessandra Pezzani
Michela Monica
Roberto Berretta
Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
Medicina
ectopic pregnancy
methotrexate
salpingectomy
tubal pregnancy
tubal rupture
maternal death
title Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
title_full Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
title_fullStr Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
title_full_unstemmed Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
title_short Predictors of Methotrexate Success and Fertility Outcomes in Tubal Ectopic Pregnancy: A Retrospective Cohort Study
title_sort predictors of methotrexate success and fertility outcomes in tubal ectopic pregnancy a retrospective cohort study
topic ectopic pregnancy
methotrexate
salpingectomy
tubal pregnancy
tubal rupture
maternal death
url https://www.mdpi.com/1648-9144/61/6/1058
work_keys_str_mv AT elisascarpelli predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT vitoandreacapozzi predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT liciaroberto predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT asyagallinelli predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT alessandrapezzani predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT michelamonica predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy
AT robertoberretta predictorsofmethotrexatesuccessandfertilityoutcomesintubalectopicpregnancyaretrospectivecohortstudy